Corticotropin Zinc Hydroxide

CHEMBL1201609 Phase 4 승인됨 Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A long-acting formulation of corticotropin (ACTH) that stimulates the adrenal glands to produce cortisol and other steroids. It is used to treat inflammatory and autoimmune conditions.

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A long-acting formulation of corticotropin (ACTH) that stimulates the adrenal glands to produce cortisol and other steroids. It is used to treat inflammatory and autoimmune conditions.

Yes, Corticotropin Zinc Hydroxide is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201609. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.